At the same meeting, the firm's board will also consider and approve the unaudited standalone & consolidated financial results of the company for the quarter ended 30 June 2023.

On the BSE, 1.15 lakh shares were traded in the counter so far compared with average daily volumes of 15,625 shares in the past two weeks.

The scrip had advanced 10.45% to hit the day's high at Rs 378.45, which is also a 52-week high for the counter.

FDC is a fully integrated research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).

The company's consolidated net profit jumped 194.2% to Rs 30.71 crore in Q4 FY23 as compared with Rs 10.44 crore in Q4 FY22. Net sales increased 27.5% year on year to Rs 434.80 crore in Q4 FY23.